Great reflections from the Phlexglobal team following the CDISC Europe discussions.

What struck me most is that the TMF conversation is changing. We are no longer talking only about better document management. We are talking about the future of clinical evidence management.

For me, three points are especially important.

1. AI will reshape TMF roles, but human expertise remains central. Across almost every industry, organizations are asking the same question: what work should AI perform, and where does human judgement remain essential?
   
   In TMF, that question is particularly important. AI can help us classify, check, enrich, identify gaps, surface risks, and accelerate review. But the TMF is part of a regulated evidence chain. Accountability, context, quality judgment, and regulatory interpretation still require experienced people.

   The future is not AI replacing TMF professionals. It is AI with humans in the loop, enabling experts to focus on risk, oversight, and the quality of evidence.

2. TMF is moving from document management to evidence management. The next evolution of TMF will be less about whether a document exists in a repository, and more about whether the clinical trial story can be reconstructed, understood, and defended.

   That means TMF leaders will need to focus on evidence completeness, traceability, metadata quality, oversight signals, decision trails, and inspection narratives. The TMF must help answer not only “where is the document?” but also “what does the evidence prove?”

3. CDISC TMF v1 can help unlock true interoperability. A common standard creates the foundation for better connection between TMF and the wider eClinical landscape. When TMF information can move more consistently across systems, we reduce friction, accelerate insights, and improve the ability to manage trials end to end.
   

   This is where standards become strategic. They help shift TMF from a downstream repository to a connected source of operational and regulatory intelligence.
   

   It is an exciting moment for our industry. The combination of standards, AI, and evidence-led thinking can fundamentally change how we manage clinical trial records and how we support regulators, sponsors, sites, and ultimately patients.

Proud of the Phlexglobal team for helping lead this conversation!

Olivier Teissedre, Chief Executive Officer

Olivier is CEO of Phlexglobal, leading the company's growth and innovation across life sciences. He combines deep TMF expertise with a digital and AI-driven vision to redefine inspection readiness. He brings 20+ years of global executive experience in healthcare technology, including roles at Cencora, BMS, and Astellas Pharma.